Anti-proliferative effects of paroxetine alone or in combination with sorafenib in HepG2 cells
DOI:
https://doi.org/10.1590/s2175-97902022e201148Keywords:
Paroxetine, Sorafenib, PharmacotherapyAbstract
Hepatocellular carcinoma (HCC) is a common cause of cancer-related death. Sorafenib is the first approved drug for the treatment of advanced HCC. Depression is frequent in cancer patients. Moreover, sorafenib might exert depression as an adverse drug reaction and paroxetine, a selective serotonin reuptake inhibitor, is a recommended pharmacotherapy. This study aimed to investigate the potential synergistic effects of paroxetine and sorafenib on HepG2 cell proliferation and death. Paroxetine and sorafenib were administered to HepG2 cells as single-agents or in combination. Cell viability was determined with XTT cell viability assay. Cellular apoptosis and DNA content were assessed by flow cytometry. The expression of anti-apoptotic Bcl-2 was examined by immunofluorescence confocal microscopy. A lower dose of sorafenib was found to be required to inhibit cell proliferation when in combination with paroxetine. Similarly, the coadministration enhanced cellular apoptosis and resulted in cell cycle arrest. Confocal imaging revealed a remarkably lower cell density and increased expression of Bcl-2 following combined treatment of paroxetine with sorafenib. To our knowledge, this is the first study demonstrating the synergistic effect of paroxetine and sorafenib in HCC and might provide a potentially promising therapeutic strategy.
Downloads
References
Abdelmageed MM, El-Naga RN, El-Demerdash E, Elmazar MM. Indole-3- carbinol enhances sorafenib cytotoxicity in hepatocellular carcinoma cells: A mechanistic study. Sci Rep. 2016;6:32733.
Amit BH, Gil-Ad I, Taler M, Bar M, Zolokov A, Weizman A. Proapoptotic and chemosensitizing effects of selective serotonin reuptake inhibitors on T cell lymphoma/ leukemia (Jurkat) in vitro. Eur Neuropsychopharmacol. 2009;19(10):726-34.
Bangaru S, Marrero JS, Singal AG. Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2020;51(1):78-89.
Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008;53(5):917-30.
Bliss CI. The toxicity of poisons applied jointly. Ann Appl Biol. 1939;26(3):585-615.
Bourin M, Chue P, Guillon Y. Paroxetine: a review. CNS Drug Rev. 2001;7(1):25-47.
Cabral L, Tiribelli C, Sukowati C. Sorafenib resistance in hepatocellular carcinoma: the relevance of genetic heterogeneity. Cancers. 2020;12(6):1576.
Chan HL, Chiu WC, Chen VC, Huang KY, Wang TN, Lee Y, et al. SSRIs associated with decreased risk of hepatocellular carcinoma: A population-based case-control study. Psycho- Oncology. 2018;27(1):187-92.
Chen S, Xuan J, Wan L, Lin H, Couch L, Mei N, et al. Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014;137(2):404-15.
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia- Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34.
Cho YW, Kim EJ, Nyiramana MM, Shin EJ, Jin H, Ryu JH, et al. Paroxetine induces apoptosis of human breast cancer MCF-7 Cells through Ca(2+)-and p38 MAP kinase- dependent ROS generation. Cancers (Basel) . 2019;11(1):64.
Chou CT, He S, Jan CR. Paroxetine-induced apoptosis in human osteosarcoma cells: activation of p38 MAP kinase and caspase-3 pathways without involvement of [Ca2+]i elevation. Toxicol Appl Pharmacol. 2007;218(3):265-73.
Davis BA, Nagarajan A, Forrest LR, Singh SK. Mechanism of paroxetine (Paxil) inhibition of the serotonin transporter. Sci Rep . 2016;6:23789.
Fang YC, Chou CT, Pan CC, Hsieh YD, Liang WZ, Chao D, et al. Paroxetine-induced Ca2+ movement and death in OC2 human oral cancer cells. Chin J Physiol. 2011;54(5):310-7.
Feng F, Zhang Z, Ding G, Hui L, Li Y, Li H. Personalized anti-cancer drug combination prediction by an Integrated Multi-level Network. BioRxiv 2020;2020.05.12.092239.
» https://doi.org/2020.05.12.092239
Fernando J, Sancho P, Fernandez-Rodriguez CM, Lledo JL, Caja L, Campbell JS, et al. Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. J Cell Physiol. 2012;227(4):1319-25.
Garten A, Grohmann T, Kluckova K, Lavery GG, Kiess W, Penke M. Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1. Int J Mol Sci. 2019;20(16):4048.
Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol Res. 2013;43(2):147-54.
Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1.
Hampton T. Cancer drug trials show modest benefit: drugs target liver, gastric, head and neck cancers. J Am Med Assoc. 2007;298(3):273-5.
Huang CC, Chen HY, Chang RH, Liao PA, Lien HH, Hung CS, et al. A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007-2015. Drug Des Devel Ther. 2019;13:397-404.
Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics. 2017;33(15):2413-15.
Jang WJ, Jung SK, Vo TTL, Jeong CH. Anticancer activity of paroxetine in human colon cancer cells: Involvement of MET and ERBB3. J Cell Mol Med. 2019;23(2):1106-15.
Khin PP, Po WW, Thein W, Sohn UD. Apoptotic effect of fluoxetine through the endoplasmic reticulum stress pathway in the human gastric cancer cell line AGS. Naunyn-Schmiedeberg’s Arch Pharmacol. 2020;393(4):537-49.
Kuwahara J, Yamada T, Egashira N, Ueda M, Zukeyama N, Ushio S, et al. Comparison of the anti-tumor effects of selective serotonin reuptake inhibitors as well as serotonin and norepinephrine reuptake inhibitors in human hepatocellular carcinoma cells. Biol Pharm Bull. 2015;38(9):1410-4.
Levkovitz Y, Gil-Ad I, Zeldich E, Dayag M, Weizman A. Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evidence for p-c-Jun, cytochrome c, and caspase-3 involvement. J Mol Neurosci. 2005;27(1):29-42.
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90.
Liu Q, Yin X, Languino LR, Altieri DC. Evaluation of drug combination effect using a Bliss independence dose-response surface model. Stat Biopharm Res. 2018;10(2):112-122.
Long F, Dong C, Jiang K, Xu Y, Chi X, Sun D, et al. Melatonin enhances the anti-tumor effect of sorafenib via AKT/p27-mediated cell cycle arrest in hepatocarcinoma cell lines. RSC Advances. 2017;7(34):21342-51.
Longo L, de Freitas LBR, Santos D, Grivicich I, Alvares-da- Silva MR. Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience. Dig Dis. 2018;36(5):377-84.
Ozunal ZG, Donmez Cakil Y, Isan H, Saglam E, Aktas RG. Sertraline in combination with sorafenib: A promising pharmacotherapy to target both depressive disorders and hepatocellular cancer. Biol Futur. 2019;70(4):341-48.
Rosetti M, Frasnelli M, Tesei A, Zoli W, and Conti M. Cytotoxicity of different selective serotonin reuptake inhibitors (SSRIs) against cancer cells. J Exp Ther Oncol. 2006;6(1):23-9.
Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20(3):175-193.
Skommer J, Brittain T, Raychaudhuri S. Bcl-2 inhibits apoptosis by increasing the time-to-death and intrinsic cell- to-cell variations in the mitochondrial pathway of cell death. Apoptosis. 2010;15(10):1223-33.
Smith HR. Depression in cancer patients: Pathogenesis, implications and treatment (Review). Oncol Letters. 2015;9(4):1509-14.
Soong RS, Anchoori RK, Roden RBS, Cho RL, Chen YC, Chieh S, et al. Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-κB signaling. BMC Cancer. 2020;20(1):386.
Tutusaus A, Stefanovic M, Boix L, Cucarull B, Zamora A, Blasco L, et al. Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. Oncotarget. 2018;9(24):16701-16717.
Villanueva A. Hepatocellular Carcinoma. N Engl J Med . 2019;380(15):1450-62.
Zhao X, Tian C, Puszyk WM, Ogunwobi OO, Cao M, Wang T, et al. OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma. Lab Invest. 2013;93(1):8-19.
Zhu YJ, Zheng B, Wang HY, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017;38(5):614-22.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
